-Secretase inhibition offers an exciting opportunity fortherapeutic intervention in the progression of Alzheimer's disease. Aseries of isonicotinamides derived from traditional aspartyl proteasetransition state isostere inhibitors has been optimized to yield lownanomolar inhibitors with sufficient penetration across the blood-brainbarrier to demonstrate
-amyloid lowering in a murine model.